[
    [
        {
            "time": "2018-03-15",
            "original_text": "Biogen SMA drug price, Novartis estimates for its treatment far too high: U.S. group",
            "features": {
                "keywords": [
                    "Biogen",
                    "SMA",
                    "drug",
                    "price",
                    "Novartis",
                    "estimates",
                    "high",
                    "U.S.",
                    "group"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-04",
            "original_text": "Roche Extends Offer Period for Spark Therapeutics Acquisition",
            "features": {
                "keywords": [
                    "Roche",
                    "Extends",
                    "Offer",
                    "Period",
                    "Spark",
                    "Therapeutics",
                    "Acquisition"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-03-10",
            "original_text": "Allergan's AMD Drug Lowers Inflammation in Phase III Study",
            "features": {
                "keywords": [
                    "Allergan",
                    "AMD",
                    "Drug",
                    "Lowers",
                    "Inflammation",
                    "Phase",
                    "III",
                    "Study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-02-20",
            "original_text": "After inking lease with cancer-fighting company, this new East Bay biotech project is full",
            "features": {
                "keywords": [
                    "lease",
                    "cancer-fighting",
                    "company",
                    "East",
                    "Bay",
                    "biotech",
                    "project"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-12",
            "original_text": "The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings",
            "features": {
                "keywords": [
                    "Daily",
                    "Biotech",
                    "Pulse",
                    "Advaxis",
                    "Offering",
                    "Roche",
                    "Spark",
                    "Tender",
                    "Offer",
                    "Extended",
                    "Ascendis",
                    "Earnings"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-01",
            "original_text": "Novartis's Alcon spinoff ousts Baer from Swiss benchmark SMI",
            "features": {
                "keywords": [
                    "Novartis",
                    "Alcon",
                    "spinoff",
                    "ousts",
                    "Baer",
                    "Swiss",
                    "benchmark",
                    "SMI"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]